Clovis Oncology Receives Breakthrough Therapy Designation for CO-1686 for the Treatment of Second-line EGFR Mutant Non-small Cell Lung Cancer (NSCLC) in Patients with the T790M Mutation
May 19, 2014Clovis Oncology's CO-1686 was granted Breakthrough Therapy designation from the FDA. This mutant EGFR inhibitor is used to treat non-small cell lung cancer patients. Approval was based on the efficacy and safety of ongoing Phase 1/2 clinical trials.
More »
Otonomy Completes Enrollment of AuriPro™ Pivotal Studies in Pediatric Patients Undergoing Ear Tube Placement Surgery
May 8, 2014Otonomy, Inc. announced their completed enrollment, with a total of 532 patients, in their two Phase 3 studies of AuriProTM for the treatment of pediatric patients with bilateral middle ear effusion requiring tympanostomy tube placement.
More »
Otonomy Raises $49 Million in Oversubscribed Financing
April 30, 2014Otonomy, Inc. announced it has secured $49 million in an oversubscribed Series D round of financing with a number of new investors. Proceeds will be used for the advancement of their product pipeline.
More »